Overview

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Status:
Completed

Trial end date:
2016-07-07

Target enrollment:

Participant gender:

Summary

This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).

Phase:

Phase 2

Details

Lead Sponsor:

Prilenia
Teva Branded Pharmaceutical Products, R&D Inc.

Collaborators:

European Huntington's Disease Network
Huntington Study Group